Valuation: Sprint Bioscience AB

Market Cap 39Cr 4.01Cr 3.51Cr 3.23Cr 2.97Cr 5.63Cr 385.93Cr 5.73Cr 15Cr 188.63Cr 15Cr 15Cr 650.16Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 39Cr 4.01Cr 3.51Cr 3.23Cr 2.97Cr 5.63Cr 385.93Cr 5.73Cr 15Cr 188.63Cr 15Cr 15Cr 650.16Cr EV / Sales 2026 *
4.55x
EV / Sales 2027 * 2.49x
Free-Float
64.78%
Yield 2026 *
-
Yield 2027 * -
1 day-4.69%
1 week-5.67%
Current month-11.59%
1 month-0.54%
3 months-9.41%
6 months+141.58%
Current year+148.98%
1 week 3.56
Extreme 3.56
3.99
1 month 3.55
Extreme 3.55
4.59
Current year 1.36
Extreme 1.355
4.59
1 year 0.48
Extreme 0.477
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
9.36
10 years 0.36
Extreme 0.36
41.9
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-4.69%-5.67%+603.85%+580.30% 4.21Cr
-1.39%-7.58%+54.00%+124.73% 5.45TCr
+3.13%+11.16%+67.30%+94.35% 5.59TCr
-0.27%-5.77%+6.75%+430.48% 2.39TCr
+1.76%-1.65%-16.86%-14.20% 2.29TCr
+3.51%+7.50%+47.81%-3.33% 2TCr
+1.94%-0.03%+38.19%-27.77% 1.75TCr
+10.00%-2.06%+210.10%+370.99% 1.54TCr
+7.69%+4.38%+56.51%+712.88% 1.52TCr
-0.39%-1.00%+26.08%+189.47% 1.4TCr
Average +2.13%+0.20%+109.37%+245.79% 2.39TCr
Weighted average by Cap. +2.10%+0.47%+52.61%+170.07%

Financials

2026 *2027 *
Net sales 8.48Cr 88.07L 77L 71.03L 65.3L 1.24Cr 85Cr 1.26Cr 3.33Cr 41Cr 3.31Cr 3.23Cr 142.76Cr 16Cr 1.61Cr 1.41Cr 1.3Cr 1.19Cr 2.26Cr 154.9Cr 2.3Cr 6.08Cr 76Cr 6.05Cr 5.91Cr 260.95Cr
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
15/26/15 SEK 3.660 -4.69% 2,45,551
14/26/14 SEK 3.840 +0.26% 67,770
13/26/13 SEK 3.830 -0.78% 2,58,970
10/26/10 SEK 3.860 +1.58% 1,75,472
09/26/09 SEK 3.800 0.00% 2,72,825

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock